917 related articles for article (PubMed ID: 16703529)
1. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
3. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
5. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
6. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
7. [Memantine].
Molinuevo JL
Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
[TBL] [Abstract][Full Text] [Related]
8. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS; Rauw G; Baker GB; Kar S
Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
[TBL] [Abstract][Full Text] [Related]
9. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Parsons CG; Stöffler A; Danysz W
Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
[TBL] [Abstract][Full Text] [Related]
10. Memantine: pharmacological properties and clinical uses.
Kumar S
Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
[TBL] [Abstract][Full Text] [Related]
11. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
12. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
13. [Advanced dementia in Alzheimer's disease and memantine].
Alberca R
Rev Neurol; 2005 Feb 1-15; 40(3):173-9. PubMed ID: 15750904
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
15. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.
Müller WE; Mutschler E; Riederer P
Pharmacopsychiatry; 1995 Jul; 28(4):113-24. PubMed ID: 7491365
[TBL] [Abstract][Full Text] [Related]
16. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
17. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
18. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
19. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
